← Product Code [OMB](/submissions/NE/subpart-b%E2%80%94neurological-diagnostic-devices/OMB) · K960273 # HARMONIE SENSA (K960273) _Stellate Systems · OMB · Apr 4, 1996 · Neurology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/NE/subpart-b%E2%80%94neurological-diagnostic-devices/OMB/K960273 ## Device Facts - **Applicant:** Stellate Systems - **Product Code:** [OMB](/submissions/NE/subpart-b%E2%80%94neurological-diagnostic-devices/OMB.md) - **Decision Date:** Apr 4, 1996 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 882.1400 - **Device Class:** Class 2 - **Review Panel:** Neurology ## Indications for Use HARMONIE™ and Sensa™ is a set of software programs which represent an improved implementation of Stellate Systems’ RHYTHM and MONITOR software. The software remains consistent with its original design objectives: - to assist in the scientific analysis of the electroencephalogram (EEG) in the field of human and animal neurophysiology. - to offer digital EEG recording by means of a personal computer and PC-based data acquisition boards. - to assist in the selection of EEG sections of potential interest and offer a variety of display, playback and review capabilities. - to complement the conventional continuous EEG recording, not replace it. The software does not make any judgment of normality or abnormality of the displayed EEG or the results of an analysis. It is not intended for extended EEG monitoring used in critical care or intra-operative settings. In no way is the software or its function represented as being in and of itself diagnostic. ## Device Story Software suite for digital EEG recording and analysis; utilizes personal computer and PC-based data acquisition boards; assists clinicians in selecting EEG segments of interest; provides display, playback, and review capabilities; intended for neurophysiology research and clinical support; does not provide automated diagnostic judgments or normality/abnormality assessments; complements rather than replaces conventional continuous EEG recording; not for critical care or intra-operative use. ## Clinical Evidence No clinical data provided; bench testing only. ## Technological Characteristics PC-based software; utilizes PC-based data acquisition boards for EEG signal input; provides digital recording, display, playback, and review functionality; non-diagnostic; intended for use in neurophysiology settings. ## Regulatory Identification An electroencephalograph is a device used to measure and record the electrical activity of the patient's brain obtained by placing two or more electrodes on the head. ## Reference Devices - RHYTHM software - MONITOR software ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service March 25, 2013 Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002 Stellate Systems c/o Mr. George Papagiannis 345 Victoria Avenue, Suite 505 Westmount, Quebec Canada H3Z 2N2 Re: K960273 Trade/Device Name: Harmonie and Sensa EEG Software Regulation Number: 21 CFR 882.1400 Regulation Name: Electroencephalograph Regulatory Class: II Product Code: OMB, OLT Dated (Date on orig SE ltr): January 17, 1996 Received (Date on orig SE ltr): January 19, 1996 Dear Mr. Papagiannis: This letter corrects our substantially equivalent letter of April 4, 1996. We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set {1} Page 2 – Mr. George Papagiannis forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Sincerely yours, Joyce M. Whang for Victor Krauthamer, Ph.D. Acting Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2} Device: HARMONIE and Sensa Software 510(k) Number: K960273 # Indications For Use HARMONIE™ and Sensa™ is a set of software programs which represent an improved implementation of Stellate Systems’ RHYTHM and MONITOR software. The software remains consistent with its original design objectives: - to assist in the scientific analysis of the electroencephalogram (EEG) in the field of human and animal neurophysiology. - to offer digital EEG recording by means of a personal computer and PC-based data acquisition boards. - to assist in the selection of EEG sections of potential interest and offer a variety of display, playback and review capabilities. - to complement the conventional continuous EEG recording, not replace it. The software does not make any judgment of normality or abnormality of the displayed EEG or the results of an analysis. It is not intended for extended EEG monitoring used in critical care or intra-operative settings. In no way is the software or its function represented as being in and of itself diagnostic. ![img-0.jpeg](img-0.jpeg) --- **Source:** [https://fda.innolitics.com/submissions/NE/subpart-b%E2%80%94neurological-diagnostic-devices/OMB/K960273](https://fda.innolitics.com/submissions/NE/subpart-b%E2%80%94neurological-diagnostic-devices/OMB/K960273) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com